Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Hockey Twitter is pissed at Elon Musk for access limits during NHL free agency frenzy
How to watch French Netflix for free from anywhere in the world
NBA 2K24 Editions: Price, Bonuses, Pre-Order
MrBeast surpasses second-most subscribed YouTube channel Cocomelon as he now aims to dethrone T-Series
U.S. Senate leader schedules classified AI briefings
Huge ‘plume’ seen coming out of nearby moon that could support alien life
Can You Pre-load Warhammer 40,000: Darktide?
7 times Black Mirror predicted the future